EMBC NASDAQ
Credit Risk of going bust: higher than 95% of companies Debt: 80.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $2.50 (down 62%), Embecta Corp. would be worth roughly what it owes.
Total debt $1.50B against a stock market value of $371.1M.
Distance to default 0.71 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $797.2M (short-term plus half of long-term), stock volatility 102.9%; Altman Z 1.33. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Parsippany, NJ 07054
US
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Morris Milton Mayo | S-Sale | 6,293 | $5.88 | 2026-09-04 |
| Kurdikar Devdatt | P-Purchase | 30,000 | $4.70 | 2026-08-12 |
| Elguicze Jacob | P-Purchase | 20,000 | $4.67 | 2026-08-12 |
| Mann Jeffrey Z | P-Purchase | 20,000 | $4.99 | 2026-08-12 |
| HOMBACH ROBERT J. | P-Purchase | 45,000 | $4.97 | 2026-08-12 |